Table 1 Demographics and other baseline characteristics
Demographic variable | Deferasirox FCT, N = 53 |
|---|---|
Age (years), mean (SD) | 32.9 (13.16) |
Age category (years), n (%) | |
< 18 | 3 (5.7) |
≥ 18 to < 50 | 46 (86.8) |
≥ 50 to < 65 | 1 (1.9) |
≥ 65a | 3 (5.7) |
Sex, n (%) | |
Male | 18 (34.0) |
Female | 35 (66.0) |
BMI (kg/m2), mean (SD) | 23.1 (3.81) |
Predominant race, n (%) | |
Caucasian | 50 (94.3) |
Asian | 1 (1.9) |
Otherb | 2 (3.8) |
Main underlying disease, n (%) | |
MDS IPSS-R risk stratification | 4 (7.5) |
Very low risk | 2 (3.8) |
Low risk | 1 (1.9) |
Intermediate risk | 1 (1.9) |
TDT | 49 (92.5) |
Time since diagnosis (years), mean (SD) | 27.1 (9.97) |
MDS | 5.1 (1.91) |
TDT | 28.9 (7.99) |
Prior ICT (received during the ECLIPSE study), n (%) | |
Deferasirox DT | 27 (50.9) |
Deferasirox FCT | 26 (49.1) |
Last ICT received before deferasirox FCT in the current study, n (%) | |
Deferiprone | 5 (9.4) |
Deferoxamine and deferiprone | 3 (5.7) |
Deferasirox monotherapy | 45 (84.9) |
Transfusion history | |
Total number of transfusions received over the past 12 months, mean (SD) | 24.8 (10.52) |
Time since last blood transfusion (days), mean (SD) | 8.0 (10.21) |
Baseline serum ferritin (µg/L), mean (SD) | 2524 (1746) |